Research programme: islet cell autoantigen 1 therapeutics - Inhibiton TherapeuticsAlternative Names: ICA-1
Latest Information Update: 12 Jan 2011
At a glance
- Originator Inhibiton Therapeutics
- Mechanism of Action Protein kinase C inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Dec 2007 Preclinical trials in Cancer in USA (unspecified route)